Sign in
Taking people in United StatesPhase 2/3

Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS

Key facts

Who runs it
Nationwide Children's Hospital
Where
Akron, Ann Arbor, Atlanta, Aurora, Birmingham, Charleston, Cincinnati, Cleveland, Columbus, Dallas, Detroit, Durham, Hershey, Houston, Indianapolis, Kansas City, Little Rock, Los Angeles, Milwaukee, Minneapolis, Oakland, Orange, Philadelphia, Pittsburgh, Richmond, Sacramento, Salt Lake City, San Antonio, San Diego, San Francisco, and Washington D.C., United StatesSee the 32 sites
Trial code
Status
Recruiting
Phase
Phase 2/3
People taking part
500 people, planned
Started
14 Jun 2022
Expected to end
31 Aug 2028
Type of study
Interventional, 5 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Anakinra
  • Placebo
Record updated
13 March 2026

Who can take part

Age
1 day to 17 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • ≥ 40 weeks corrected gestational age to < 18 years; AND
  • Admission to the PICU or CICU; AND
  • Onset of ≥ 2 new organ dysfunctions within the last 3 calendar days (compared to pre-sepsis baseline) as measured by the modified Proulx criteria; AND
  • Documented or suspected infection as the MODS inciting event

Who cannot take part

  • Current or prior diagnosis of hemophagocytic lymphohistiocytosis or macrophage activation syndrome; OR
  • Receipt of anakinra within the previous 28 days; OR
  • Previous enrollment in the TRIPS study
  • Moribund condition in which the patient is unlikely to survive the next 48 hours in opinion of the clinical team; OR
  • Known allergy to anakinra, or E. coli-derived products; OR
  • Peripheral white blood cell count < 1,000 cells/mm3 as the result of myeloablative therapy OR receipt of myeloablative therapy within the previous 14 days; OR
  • Weight <3kg; OR
  • Limitation of care order at the time of screening; OR
  • Patients at high likelihood of progression to brain death in opinion of the clinical team; OR
  • Known pregnancy; OR
  • Lactating females; OR
  • Resolution of MODS by MODS Day 2; OR

Where in United States

  • Akron Children's HospitalAkron, United StatesContact: Christopher Page-Goertz, MDTaking people
  • CS Mott Children's HospitalAnn Arbor, United StatesContact: Michael QuasneyTaking people
  • Children's Hospital of AtlantaAtlanta, United StatesContact: Jocelyn Grunwell, MD, PhDTaking people
  • Children's Hospital ColoradoAurora, United StatesContact: Eva NozikTaking people
  • Children's of AlabamaBirmingham, United StatesContact: Michele Kong, MDTaking people
  • Medical University of South CarolinaCharleston, United StatesContact: John CostelloTaking people
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Natalja Stanski, MDTaking people
  • Rainbow Babies and Children's HospitalCleveland, United StatesContact: Kenneth RemyTaking people
  • Nationwide Children's HospitalColumbus, United StatesContact: Mark HallTaking people
  • University of Texas, SouthwesternDallas, United StatesContact: Matthew BorgmanTaking people
  • Children's Hospital of MichiganDetroit, United StatesContact: Kathleen Meert, MDTaking people
  • Duke UniversityDurham, United StatesContact: Christoph HornikTaking people
  • Pennsylvania State UniversityHershey, United StatesContact: Neal ThomasTaking people
  • Texas Children's HospitalHouston, United StatesContact: Ayse ArikanTaking people
  • Riley Children's HospitalIndianapolis, United StatesContact: Daniel Cater, MDTaking people
  • Mercy Children's HospitalKansas City, United StatesContact: Yong HanTaking people
  • Arkansas Children's HospitalLittle Rock, United StatesContact: Ronald SandersTaking people
  • Children's Hospital of Los AngelesLos Angeles, United StatesContact: Robinder KhemaniTaking people
  • Medical College of WisconsinMilwaukee, United StatesContact: Nathan ThompsonNot yet recruiting
  • Children's Hospital of MinnesotaMinneapolis, United StatesContact: Alberto OriolesNot yet recruiting
  • University of MinnesotaMinneapolis, United StatesContact: Marie SteinerTaking people
  • Benioff Children's Hospital - OaklandOakland, United StatesContact: Natalie CvijanovichTaking people
  • Children's Hospital of Orange CountyOrange, United StatesContact: Adam SchwarzNot yet recruiting
  • Children's Hospital of PhiladelphiaPhiladelphia, United StatesContact: Julie FitzgeraldTaking people
  • Children's Hospital of PittsburghPittsburgh, United StatesContact: Joseph CarcilloTaking people
  • Virginia Commonwealth UniversityRichmond, United StatesContact: Nikki Miller-FergusonTaking people
  • University of California - DavisSacramento, United StatesContact: MoonJoo Han, MDTaking people
  • Primary Children's HospitalSalt Lake City, United StatesContact: Jill SweneyTaking people
  • Children's Hospital of San AntonioSan Antonio, United StatesContact: Kirstin HenleyTaking people
  • Rady Children's HospitalSan Diego, United StatesContact: Nicole CoufalTaking people
  • Benioff Children's Hospital - Mission BaySan Francisco, United StatesContact: Patrick McQuillenTaking people
  • Children's National Medical CenterWashington D.C., United StatesContact: Sonali BasuTaking people

About the trial

What the trial wants to find out

The TRIPS study is a prospective, multi-center, double-blind, adaptively randomized, placebo-controlled clinical trial of the drug anakinra for reversal of moderate to severe hyperinflammation in children with sepsis-induced multiple organ dysfunction syndrome (MODS).

The 5 groups in the trial

  • Anakinra 4 mg/kg/dayExisting treatment, for comparison

    IV Anakinra 4mg/kg/day x 7 days

    Treatment: Anakinra

  • Anakinra 8 mg/kg/dayExisting treatment, for comparison

    IV Anakinra 8 mg/kg/day x 7 days

    Treatment: Anakinra

  • Anakinra 12 mg/kg/dayExisting treatment, for comparison

    IV Anakinra 12 mg/kg/day x 7 days

    Treatment: Anakinra

  • Anakinra 16 mg/kg/dayExisting treatment, for comparison

    IV Anakinra 16 mg/kg/day x 7 days

    Treatment: Anakinra

  • PlaceboPlacebo, for comparison

    IV placebo x 7 days

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Targeted Reversal of Inflammation in Pediatric Sepsis-induced MODS (TRIPS)
Publications
Record updated
13 March 2026